ALG1-CDG — GDP-Man:GlcNAc2-PP-dolichol mannosyltransferase deficiency (OMIM #608540), designated CDG-Ik, a rare autosomal recessive congenital disorder of glycosylation caused by biallelic pathogenic variants in ALG1 (encoding GDP-Man:GlcNAc2-PP-dolichol mannosyltransferase — the endoplasmic reticulum-resident enzyme that catalyzes the first mannosylation step in the stepwise assembly of the dolichol-linked N-glycan precursor; specifically, ALG1 transfers a mannose residue from the activated donor GDP-mannose to the GlcNAc2-PP-dolichol (Man0GlcNAc2-PP-Dol) acceptor substrate, forming Man1GlcNAc2-PP-dolichol, the first elongation product of the dolichol-linked oligosaccharide assembly chain that will eventually produce the complete Glc3Man9GlcNAc2-PP-dolichol precursor after successive additions by ALG2 [adds Man2], ALG11 [adds Man3, Man4, Man5], and the subsequent flippase-mediated translocation into the ER lumen for assembly of the outer mannose arms and glucose capping; ALG1 deficiency → failure to add the first mannose → accumulated GlcNAc2-PP-dolichol substrate → truncated dolichol-linked oligosaccharide precursor → transfer of severely underglycosylated GlcNAc2 or Man1GlcNAc2 structures to protein asparagine residues by the oligosaccharyltransferase complex → severely hypoglycosylated glycoproteins, including coagulation factors, complement proteins, lysosomal enzymes, hormone-binding proteins, and structural glycoproteins) — CDT analysis shows a Type I CDG pattern with marked reduction of disialotransferrin and asialo-transferrin representing the severely truncated glycan transfer; CLINICAL FEATURES: severe early-onset neurological disease dominating the clinical picture — hypotonia from birth (generalized axial and appendicular hypotonia), seizures (often presenting as infantile spasms with hypsarrhythmia on EEG in the first weeks to months of life, constituting a CDG epileptic encephalopathy syndrome), global developmental delay across motor, language, and cognitive domains, failure to thrive from feeding difficulties, hepatomegaly with elevated transaminases, and coagulopathy (reduced factor XI, protein C, and protein S from glycosylation-dependent coagulation factor instability); recurrent infections from immune dysfunction; some patients manifest dysmorphic features; no disease-modifying therapy exists; management is symptomatic — anti-epileptic drugs (seizure control is particularly important as ALG1-CDG seizures can be refractory to multiple anti-epileptic drugs and infantile spasm-specific regimens [ACTH, vigabatrin] with 2-week interval response assessment are required), vitamin K and coagulation support for coagulopathy, and investigational mannose supplementation (theoretical basis from mannose-responsive CDG syndromes MPI-CDG and PMM2-CDG but not proven for ALG1-CDG).
ALG1-CDG technology platforms — encompassing the transferrin isoelectric focusing and mass spectrometry platforms establishing the CDG Type I biochemical diagnosis with the characteristic severely truncated glycan pattern, the ALG1 molecular genetics platforms performing biallelic variant identification, the EEG platforms monitoring infantile spasms and hypsarrhythmia, the anti-epileptic drug monitoring platforms tracking ACTH and vigabatrin infantile spasm response and subsequent epilepsy management, the brain MRI platforms documenting progressive structural changes, the coagulation factor monitoring platforms tracking factor XI, protein C, protein S, and coagulopathy in the context of pre-procedural surgical and lumbar puncture planning, the hepatic function surveillance platforms, the CDT repeat monitoring platforms for longitudinal glycosylation biomarker tracking, the global developmental assessment platforms tracking motor, language, and cognitive trajectory, the multi-disciplinary rehabilitation scheduling platforms (physiotherapy, occupational therapy, speech-language pathology, assistive technology), the CDG Care network and International Working Group on CDG (IWGCDG) registry platforms, and pre-procedural coagulation assessment scheduling systems — must maintain the availability and performance standards required by the infantile spasm urgency, coagulopathy management complexity, neurodevelopmental surveillance obligations, hepatic monitoring demands, and multi-specialty rehabilitation coordination complexity of ALG1-CDG. This guide explains why ALG1-CDG tech platforms need dedicated monitoring, what components to monitor, and how to build a monitoring strategy matched to the infantile spasm urgency, coagulopathy management complexity, neurodevelopmental surveillance obligations, hepatic monitoring demands, and multi-specialty rehabilitation coordination complexity of ALG1-CDG.
Why ALG1-CDG Tech Platforms Require Specialized Monitoring Attention
ALG1-CDG management presents monitoring challenges shaped by the infantile spasm urgency, the coagulopathy management complexity, the neurodevelopmental surveillance obligations, the hepatic monitoring demands, the pre-procedural coagulation assessment requirements, and the multi-specialty rehabilitation coordination complexity of a CDG syndrome with a severe early-onset neurological phenotype centered on epileptic encephalopathy: the infantile spasm urgency — infantile spasms are the most urgent seizure emergency in early childhood; hypsarrhythmia on EEG combined with epileptic spasms defines West syndrome, a catastrophic epileptic encephalopathy; the response to ACTH or vigabatrin must be assessed at 2-week intervals because failure to achieve hypsarrhythmia cessation within 2 weeks mandates escalation to alternative treatment; each additional week of active hypsarrhythmia produces additional epileptic encephalopathy injury to the developing brain; platform failures disrupting EEG platforms during ACTH or vigabatrin treatment response monitoring delay the 2-week response assessment that determines whether treatment is working or whether urgent escalation to a second-line infantile spasm regimen is required; the coagulopathy management complexity — concurrent factor XI, protein C, and protein S deficiency creates a paradoxical coagulopathy with hemorrhagic and thrombotic risk, with particular importance in the pre-procedural context because LP (lumbar puncture for CSF examination), MRI sedation, gastrostomy surgery, and other procedures require pre-procedural hematology consultation and coagulation assessment; the neurodevelopmental surveillance obligation — global developmental delay across motor, language, and cognitive domains requires parallel rehabilitation scheduling across physiotherapy, occupational therapy, and speech-language pathology; the hepatic monitoring demand — elevated transaminases require quarterly LFT monitoring and biannual liver ultrasound; and the pre-procedural coagulation assessment requirement — every procedure requires documented coagulation review before scheduling.
EEG platforms are the primary infantile spasm monitoring infrastructure in ALG1-CDG — failures during the ACTH or vigabatrin treatment response window delay the 2-week hypsarrhythmia assessment that determines whether epileptic spasm treatment is working or whether immediate escalation to a second-line regime is required to halt the epileptic encephalopathy that is the dominant injury mechanism to the developing brain in ALG1-CDG. Infantile spasm treatment urgency is time-critical at a 2-week granularity: the ACTH or vigabatrin treatment initiation triggers a 14-day response window during which daily EEG (or at minimum day-14 EEG) documents whether hypsarrhythmia has resolved; hypsarrhythmia cessation at 2 weeks predicts spasm-free outcomes significantly better than persistent hypsarrhythmia requiring escalation; the brain areas most vulnerable to epileptic encephalopathy injury during active hypsarrhythmia are the frontal and temporal association areas that subserve the language, executive function, and social cognition that are the targets of ALG1-CDG developmental rehabilitation; EEG platform failures during the 2-week response monitoring window delay the treatment escalation decision that protects developing cognitive function. Monitor at 1-minute intervals during clinical hours. Alert immediately.
Pre-procedural coagulation assessment platforms are the surgical safety monitoring tools in ALG1-CDG — failures during coagulation factor assessment before lumbar puncture, gastrostomy surgery, neuroimaging sedation procedures, or any surgical intervention prevent the hematology-guided perioperative coagulopathy management that protects against hemorrhagic complications in a patient with combined factor XI, protein C, and protein S deficiency. The coagulopathy of ALG1-CDG creates a complex pre-procedural decision framework: factor XI deficiency at 30–40% of normal does not automatically require factor XI concentrate prophylaxis for all procedures (factor XI is a contact pathway factor and its bleeding risk correlates poorly with activity levels), but protein C and protein S deficiency at 25–30% of normal increases thrombotic risk that must be weighed against anticoagulation-exacerbated hemorrhagic risk in the same patient; hematology consultation before every lumbar puncture, gastrostomy insertion, or surgical procedure is standard practice; platform failures disrupting coagulation monitoring systems before procedures allow procedures to proceed without hematology-guided perioperative planning. Monitor at 1-minute intervals during clinical and laboratory hours. Alert immediately.
CDT and transferrin monitoring platforms are the longitudinal glycosylation biomarker tracking infrastructure in ALG1-CDG — repeated CDT measurements every 6 months provide serial documentation of the N-glycosylation status biomarker that tracks disease course and may contribute to assessing response if disease-modifying therapies emerge from investigational studies. ALG1-CDG has no currently established disease-modifying treatment, but the CDT serves as the most accessible systemic glycosylation biomarker; the severely truncated glycan pattern in ALG1-CDG (GlcNAc2 or Man1GlcNAc2 transfer) produces a more severely abnormal CDT pattern than many other Type I CDG syndromes; serial CDT monitoring contributes to the natural history documentation that supports eventual clinical trial design. Monitor at 1-minute intervals during laboratory hours. Alert immediately.
What to Monitor on a ALG1-CDG Care Tech Platform
EEG Monitoring — Infantile Spasms, Hypsarrhythmia, and Epilepsy Surveillance
Monitor EEG records (EEG at seizure onset — infantile spasms with hypsarrhythmia in the first weeks to months of life define the West syndrome presentation in many ALG1-CDG patients; EEG background characterization — hypsarrhythmia is defined as a chaotic, high-amplitude, non-synchronized EEG pattern with multifocal epileptiform discharges on a disorganized background; EEG at 14 days after ACTH or vigabatrin initiation — the critical 2-week response assessment that determines whether hypsarrhythmia has resolved and spasms have stopped; EEG at 14 days after initiation of second-line infantile spasm regimen — tetracosactide [Synacthen] HD, nitrazepam, topiramate, or pyridoxine — if first-line failed; serial EEG every 6–12 months after initial spasm control to monitor for emergence of other epilepsy syndromes — Lennox-Gastaut syndrome, focal epilepsy, or myoclonic-atonic epilepsy as late-developing seizure phenotypes in ALG1-CDG; EEG during acute seizure escalation and status epilepticus management; EEG background tracking for progressive encephalopathy), infantile spasm treatment records (ACTH protocol records — dose, route, duration, taper schedule, cushingoid side effect monitoring, hypertension monitoring during ACTH; vigabatrin records — dose records, visual field monitoring schedule [vigabatrin-associated peripheral visual field constriction requires ophthalmology surveillance]; 2-week response assessment records; second-line anti-epileptic drug selection records for non-responders; ketogenic diet initiation records for drug-refractory infantile spasms; ACTH re-challenge records for relapsed hypsarrhythmia), and subsequent epilepsy management records (anti-epileptic drug level monitoring for narrow-therapeutic-window drugs; seizure frequency and type diary records — focal, generalized tonic-clonic, myoclonic, absence, atonic seizure types documented longitudinally; valproate-coagulopathy interaction monitoring given factor XI and protein C deficiency; hepatic function monitoring during hepatotoxic anti-epileptic drug use; status epilepticus management records; vagal nerve stimulator implant and programming records) — at a 1-minute interval during clinical hours. Alert immediately.
Coagulation Monitoring and Pre-Procedural Assessment
Monitor coagulation factor records (factor XI activity — reduced in ALG1-CDG from glycosylation-dependent coagulation factor instability; protein C activity — reduced, increasing thrombotic risk; protein S activity — reduced; PT/INR for functional coagulation assessment of the extrinsic pathway; aPTT for intrinsic pathway assessment; fibrinogen — glycoprotein with N-glycan modification; platelet count and function; thromboelastography records for global coagulation assessment in pre-procedural planning; coagulation factor trends during anti-epileptic drug initiation — valproate may exacerbate platelet function defects; D-dimer and antithrombin monitoring for thrombotic risk assessment), pre-procedural coagulation assessment records (hematology pre-procedural consultation records before every lumbar puncture — factor XI activity and protein C/S levels reviewed; gastrostomy surgery pre-procedural records — factor XI and protein C/S, surgical bleeding risk stratification, factor XI concentrate availability assessment, post-operative thromboprophylaxis decision; neuroimaging sedation procedure records — even for sedation-only procedures, coagulopathy documents the need for IV access protocols and hemorrhagic complication monitoring; neurosurgical procedure records in patients with intractable epilepsy considered for corpus callosotomy or resective surgery — the most complex pre-procedural coagulopathy planning scenario), and hemorrhagic and thrombotic event records (hemorrhagic event documentation — intracranial hemorrhage during status epilepticus or with valproate; mucosal hemorrhage; soft tissue hematoma; thrombotic event documentation — venous thromboembolism in the context of protein C/S deficiency; anticoagulation management in thromboembolism with underlying coagulopathy; vitamin K supplementation records for prothrombin-dependent factor support) — at a 1-minute interval during clinical and laboratory hours. Alert immediately.
CDT Analysis and ALG1 Molecular Genetics
Monitor CDT and transferrin records (CDT/serum transferrin isoelectric focusing or mass spectrometry at diagnosis — the Type I CDG pattern with characteristic severely truncated glycan transfer; CDT mass spectrometry quantifying the Man1GlcNAc2 or GlcNAc2 transfer products that distinguish ALG1-CDG from other Type I CDG syndromes with more advanced precursor truncation; serial CDT monitoring every 6 months as a longitudinal N-glycosylation biomarker tracking disease course; the confounding effects of iron deficiency, hemolysis, hepatic disease, and concurrent medications on CDT interpretation; CDT repeat monitoring schedule — every 6 months providing the glycosylation biomarker dataset that supports ALG1-CDG natural history documentation and eventual clinical trial readiness), ALG1 molecular testing records (ALG1 gene sequencing confirming biallelic pathogenic variants; variant classification by ACMG criteria; genotype-phenotype correlation records in the growing ALG1-CDG cohort — limited by small patient numbers, but severe loss-of-function variants correlate with more severe clinical presentations; family cascade evaluation — 25% sibling recurrence risk; parental carrier confirmation; at-risk sibling evaluation with CDT analysis and ALG1 molecular testing; presymptomatic newborn diagnosis enabling early monitoring and intervention initiation before infantile spasm onset; prenatal molecular testing records), and CDG Care and IWGCDG registry records (CDG Care registry enrollment; IWGCDG natural history study participation; research protocol records including mannose supplementation investigational trials; ALG1-CDG genotype-phenotype correlation database contribution; international CDG registry data transfer records) — at a 1-minute interval during laboratory hours. Alert immediately.
Brain MRI and Neuroimaging Surveillance
Monitor brain MRI records (brain MRI at diagnosis — documentation of structural brain abnormalities present at initial presentation; white matter changes — periventricular white matter T2/FLAIR signal abnormality; cortical atrophy assessment; cerebellar and brainstem structural assessment; corpus callosum assessment — thin or hypoplastic corpus callosum in some ALG1-CDG patients; cortical malformation documentation; MRI characterization during infantile spasm management — whether hypsarrhythmia correlates with progressive structural changes; serial brain MRI annually to document progressive atrophy and white matter changes; diffusion-weighted MRI during acute neurological events; MR spectroscopy in research-protocol centers; neuroimaging platform availability for sedation procedures given the pre-procedural coagulopathy assessment requirements), neuroimaging procedure planning records (sedation protocol records — procedural sedation for MRI in hypotonic, medically complex infants requires anesthesia planning; pre-procedural coagulation review before IV access and sedation procedures; NPO protocol records; post-sedation monitoring records; neuroimaging frequency schedule — brain MRI annually documenting progressive changes, with additional imaging triggered by acute neurological events, status epilepticus, or clinical regression), and visual field monitoring records (vigabatrin-associated peripheral visual field constriction is an important safety monitoring obligation if vigabatrin is used for infantile spasm treatment; ophthalmologic visual field testing scheduling at vigabatrin initiation and at 3, 6, and 12 months; Goldmann or Humphrey perimetry records; ERG records for vigabatrin retinotoxicity monitoring in non-verbal patients who cannot perform perimetry) — at a 1-minute interval during clinical hours. Alert immediately.
Hepatic Monitoring and Nutritional Support
Monitor hepatic function records (ALT and AST quarterly — elevated in ALG1-CDG from hepatocyte glycoprotein dysfunction and the CDG hepatopathy; GGT; albumin for hepatic synthetic function and nutritional status; total protein; bilirubin; PT/INR for hepatic synthetic function assessment — which overlaps with the coagulopathy monitoring; hepatic ultrasound biannually for hepatomegaly assessment and hepatic architecture; monitoring of hepatotoxic anti-epileptic drugs — phenytoin, carbamazepine, valproate, all carrying hepatotoxicity risk in a patient with underlying CDG hepatopathy; the priority of avoiding hepatotoxic anti-epileptic drugs in ALG1-CDG; documentation of transaminase trends during vigabatrin, ACTH, and other anti-epileptic drug initiations), nutritional support records (feeding difficulties from hypotonia contributing to nutritional challenges in ALG1-CDG; gastrostomy placement records — tube feeding for patients unable to maintain adequate oral caloric intake; caloric intake and growth monitoring; failure to thrive assessment; dietitian consult records; vitamin K supplementation for prothrombin-dependent factor support in coagulopathy; mineral and trace element supplementation monitoring; anthropometric records — weight, length/height, head circumference), and gastroenterology records (GI dysmotility records in hypotonic CDG patients; gastroesophageal reflux assessment and management; gastrostomy site care records; fundoplication records for severe GERD; gut glycoprotein dysfunction assessment — CDG hepatopathy and gut motility dysfunction share the glycoprotein dependency mechanism) — at a 1-minute interval during clinical and laboratory hours. Alert immediately.
Neurodevelopmental Rehabilitation Scheduling
Monitor physiotherapy records (physiotherapy from diagnosis — hypotonia from birth requires early physiotherapy intervention; gross motor milestone monitoring; supported sitting, standing, and walking program records; equipment assessment — trunk support seating, standing frames, posterior walkers; weekly or biweekly physiotherapy scheduling records; aquatic therapy records; home exercise program records and family training documentation), occupational therapy records (fine motor assessment and intervention — hand function, grasping, feeding, self-care; feeding therapy records — oral feeding skill assessment, adaptive utensil selection, positioning for safe feeding; sensory processing assessment; adaptive equipment prescription — AAC devices for communication support, adaptive seating, positioning aids; school occupational therapy records; IEP-linked occupational therapy goal documentation), speech-language pathology records (oromotor assessment for feeding and communication; augmentative and alternative communication [AAC] assessment and implementation records; pre-verbal communication assessment for infants; language developmental monitoring; school SLP records; feeding team involvement records for patients with gastrostomy and concurrent oral feeding readiness), and assistive technology and school support records (assistive technology assessment biannually for communication, mobility, and daily living needs; school support planning biannually — IEP records with educational therapist, special education teacher, and support worker allocation; transition planning records for post-school adulthood; supported living planning for adults with severe intellectual disability; CDG community family support network referral records) — at a 1-minute interval during clinical hours. Alert immediately.
Authentication and Clinical Identity
Monitor authentication at 1-minute intervals, 24/7. ALG1-CDG management coordinates across metabolic medicine (CDT analysis, ALG1 enzyme activity, glycosylation biomarker monitoring), molecular genetics (ALG1 sequencing, family cascade, prenatal testing), pediatric and adult neurology (infantile spasm management, ACTH and vigabatrin response monitoring, subsequent epilepsy management, EEG surveillance, white matter disease follow-up), neurophysiology (EEG telemetry for infantile spasm management and subsequent epilepsy), hematology (coagulopathy management, pre-procedural coagulation assessment, anti-epileptic drug-coagulopathy interaction monitoring), hepatology (liver disease surveillance, hepatotoxic drug safety monitoring), dietetics (nutritional support, gastrostomy management, vitamin K supplementation), gastroenterology (motility, reflux, gastrostomy), ophthalmology (vigabatrin visual field monitoring), physiotherapy (hypotonia rehabilitation, gross motor development), occupational therapy (fine motor, feeding, daily living, AAC), speech-language pathology (communication, feeding, oromotor), assistive technology services, school and developmental disability support services, and CDG Care / IWGCDG registry coordination — authentication failures block the integrated multi-platform epilepsy-management, coagulopathy-management, rehabilitation-scheduling, and glycosylation-monitoring care coordination that the infantile spasm urgency, coagulopathy management complexity, neurodevelopmental surveillance obligations, and multi-specialty rehabilitation coordination demands require across ALG1-CDG.
SSL Certificates
Monitor SSL certificate expiry across all CDT analysis platforms, ALG1 molecular genetics systems, EEG and video-EEG telemetry systems, anti-epileptic drug level monitoring platforms, coagulation factor monitoring platforms, pre-procedural assessment scheduling systems, brain MRI scheduling platforms, hepatic function laboratory systems, nutritional support and gastrostomy management platforms, physiotherapy scheduling systems, occupational therapy records platforms, speech-language pathology platforms, assistive technology scheduling systems, vigabatrin visual field monitoring platforms, school support planning systems, and IWGCDG / CDG Care registry platforms. Certificate errors disrupt the integrated multi-platform care infrastructure that ALG1-CDG management requires across all seizure, coagulopathy, nutritional, and rehabilitative domains.
HIPAA and Rare Genetic Disease Patient Privacy Considerations
ALG1-CDG technology platforms handle highly sensitive PHI encompassing ALG1 molecular testing results (biallelic pathogenic variants identifying both parents as obligate carriers with 25% recurrence risk per pregnancy; family cascade implications for extended family), CDT records establishing the CDG biochemical diagnosis with the severely truncated glycan pattern, EEG records documenting infantile spasms and hypsarrhythmia (West syndrome documentation with implications for long-term disability prognosis assessments, supported living resource allocation, and guardianship proceedings), ACTH treatment records (systemic corticosteroid exposure records with implications for HPA axis evaluation and long-term growth monitoring), vigabatrin treatment records with visual field monitoring (with implications for AAC device needs if visual field constriction develops), anti-epileptic drug records (with implications for health and life insurance underwriting and professional licensing), intellectual disability severity documentation (with implications for guardianship, supported living, disability benefits, and educational resource allocation across a lifetime), coagulation factor deficiency records (pre-procedural coagulopathy documentation with implications for surgical planning and anesthesia risk disclosure), hepatic function records, brain MRI records documenting progressive white matter changes and cortical atrophy (with long-term functional prognosis implications), gastrostomy placement records (with implications for long-term nutritional dependency disclosure), and physiotherapy, occupational therapy, and AAC records.
The global rarity of ALG1-CDG — fewer than 50 cases reported in the literature — means that clinical disclosure of the diagnosis within the rare disease community has a high re-identification risk. The combination of infantile spasms, severe global developmental delay, hypotonia, and coagulopathy that characterizes ALG1-CDG creates a distinctive phenotypic signature that may re-identify patients in clinical publications or case presentations within the CDG rare disease network without disclosure of the specific diagnosis.
Alerting Strategy for ALG1-CDG Tech Platforms
Immediate clinical-hours alerting for EEG and infantile spasm monitoring platforms: EEG platforms are the primary infantile spasm urgency monitoring tools in ALG1-CDG — failures during ACTH or vigabatrin treatment response monitoring delay the 2-week hypsarrhythmia assessment that determines whether treatment is working or whether immediate escalation to a second-line infantile spasm regimen is required to halt epileptic encephalopathy injury to the developing brain.
Immediate clinical-hours and laboratory-hours alerting for coagulation factor monitoring platforms: Coagulation factor monitoring and pre-procedural assessment platforms are the surgical safety monitoring tools in ALG1-CDG — failures before lumbar puncture, gastrostomy surgery, neuroimaging sedation, or any surgical procedure prevent the hematology-guided perioperative coagulopathy management that protects against hemorrhagic complications in a patient with combined factor XI, protein C, and protein S deficiency.
Immediate laboratory-hours alerting for anti-epileptic drug level monitoring platforms: Drug level monitoring for narrow-therapeutic-window anti-epileptic drugs requires immediate alerting during laboratory hours for therapeutic drug level assessment during dose titration, status epilepticus management, and drug toxicity monitoring in a patient with concurrent CDG hepatopathy.
Immediate laboratory-hours alerting for CDT transferrin analysis platforms: CDT isoelectric focusing and mass spectrometry platforms require immediate alerting during laboratory hours — the Type I CDG pattern with severely truncated glycan transfer is the biochemical gateway diagnostic step for ALG1-CDG, and 6-monthly repeat monitoring contributes to the glycosylation biomarker dataset for natural history documentation.
Immediate laboratory-hours alerting for hepatic function monitoring platforms: Hepatic function monitoring platforms require immediate alerting during laboratory hours for CDG hepatopathy surveillance and hepatotoxic anti-epileptic drug safety monitoring.
Sustained-failure alert (10–15 minutes): ALG1 molecular genetics platforms, family cascade evaluation platforms, prenatal genetic testing platforms, brain MRI scheduling platforms, vigabatrin visual field monitoring platforms, physiotherapy scheduling platforms, occupational therapy records, speech-language pathology platforms, assistive technology scheduling systems, school support planning systems, and IWGCDG / CDG Care registry platforms.
30-day advance warning: SSL certificates across all domains.
Vigilmon's multi-region monitoring confirms ALG1-CDG platform availability from the metabolic medicine centers, pediatric neurology programs and infantile spasm management units, neurophysiology departments, molecular genetics laboratories, hematology services, hepatology departments, dietetics services, physiotherapy and occupational therapy programs, speech-language pathology departments, assistive technology centers, and IWGCDG / CDG Care registry coordination programs that serve the ALG1-CDG population.
Status Page for ALG1-CDG Care Team Communication
A real-time status page gives metabolic medicine teams processing CDT isoelectric focusing and ALG1 enzyme activity results, pediatric neurologists managing infantile spasm treatment with ACTH and vigabatrin and monitoring 2-week EEG response, neurophysiologists reporting routine and video-EEG telemetry for hypsarrhythmia resolution assessment, hematologists managing the pre-procedural coagulopathy assessment and anti-epileptic drug-coagulopathy interaction monitoring, hepatologists monitoring CDG hepatopathy and hepatotoxic drug safety, molecular genetics teams performing ALG1 sequencing and family cascade evaluations, dietitians managing gastrostomy nutrition and vitamin K supplementation, physiotherapists managing hypotonia rehabilitation and gross motor development, occupational therapists managing fine motor, feeding, and AAC programs, speech-language pathologists managing oromotor and communication programs, ophthalmologists monitoring vigabatrin visual field toxicity, assistive technology specialists, and families managing EEG scheduling, anti-epileptic drug administration, feeding protocols, and seizure diaries at home — immediate platform visibility without requiring inbound IT support contact.
Include the status page URL in ALG1-CDG clinic infantile spasm escalation protocols, neurophysiology EEG downtime procedures, hematology pre-procedural coagulopathy assessment backup plans, and anti-epileptic drug toxicity emergency response procedures.
Vigilmon Setup for ALG1-CDG Tech Platforms
A practical starting configuration:
| Monitor | Check Interval | Alert Channel | |---------|----------------|---------------| | Authentication | 1 min | Slack + PagerDuty (24/7) | | EEG (infantile spasm monitoring, hypsarrhythmia assessment) | 1 min | Slack + PagerDuty (clinical hours) | | Video-EEG telemetry (spasm semiology and response monitoring) | 1 min | Slack + PagerDuty (clinical hours) | | ACTH response EEG at day 14 (hypsarrhythmia resolution) | 1 min | Slack + PagerDuty (clinical hours) | | Anti-epileptic drug levels (VGB, valproate, phenobarbital monitoring) | 1 min | Slack + PagerDuty (lab hours) | | Coagulation factors (XI, protein C, protein S, PT, aPTT) | 1 min | Slack + PagerDuty (lab hours) | | Pre-procedural coagulation assessment scheduling | 1 min | Slack + PagerDuty (clinical hours) | | CDT/transferrin IEF and MS (diagnosis + 6-monthly monitoring) | 1 min | Slack + PagerDuty (lab hours) | | ALG1 gene sequencing and del/dup analysis | 1 min | Slack + PagerDuty (lab hours) | | Hepatic function (ALT, AST, GGT, albumin — quarterly) | 1 min | Slack + PagerDuty (lab hours) | | Hepatic ultrasound scheduling (biannual) | 1 min | Slack + PagerDuty (clinical hours) | | Brain MRI scheduling (annual progressive changes documentation) | 1 min | Slack + PagerDuty (clinical hours) | | Vigabatrin visual field monitoring (ophthalmology, 3/6/12 months) | 2 min | Slack (clinical hours) | | Physiotherapy scheduling (weekly/biweekly hypotonia rehabilitation) | 2 min | Slack (clinical hours) | | Occupational therapy records (feeding, fine motor, AAC) | 2 min | Slack (clinical hours) | | Speech-language pathology scheduling (oromotor, communication) | 2 min | Slack (clinical hours) | | Assistive technology assessment scheduling (biannual) | 2 min | Slack (clinical hours) | | Gastrostomy and nutritional support records | 2 min | Slack (clinical hours) | | School support and IEP planning (biannual) | 2 min | Slack (business hours) | | Family cascade molecular testing | 2 min | Slack (lab hours) | | Prenatal and preimplantation genetic testing | 2 min | Slack (business hours) | | CDG Care / IWGCDG registry data transfer | 2 min | Slack (business hours) | | SSL: all domains | Daily | Email (30-day warning) |
Getting started:
- Create a free account at vigilmon.online
- Add authentication endpoints at 1-minute intervals with 24/7 alerting
- Configure EEG and video-EEG platforms with immediate clinical-hours alerting — the primary infantile spasm urgency monitoring infrastructure in ALG1-CDG, where the 2-week hypsarrhythmia assessment after ACTH or vigabatrin initiation determines whether treatment is working or whether immediate escalation to a second-line regimen is required to halt epileptic encephalopathy injury to the developing brain
- Add ACTH day-14 EEG response assessment scheduling with immediate clinical-hours alerting — the scheduled EEG at 2 weeks after treatment initiation is the most time-critical monitoring obligation in infantile spasm management, and platform failures causing a delay of even 1–2 days extend the window of potential hypsarrhythmia-related encephalopathy
- Configure anti-epileptic drug level monitoring with immediate laboratory-hours alerting for vigabatrin level assessment (though vigabatrin dosing is not guided by plasma levels, monitoring plasma amino acids and GABA is relevant in some protocols), valproate levels, and subsequent epilepsy drug monitoring in the context of CDG hepatopathy
- Add coagulation factor monitoring platforms (factor XI, protein C, protein S, PT, aPTT) with immediate laboratory-hours alerting for baseline coagulopathy documentation and anti-epileptic drug-coagulopathy interaction monitoring
- Configure pre-procedural coagulation assessment scheduling with immediate clinical-hours alerting — every lumbar puncture, gastrostomy insertion, neuroimaging sedation procedure, and surgical intervention requires documented pre-procedural hematology coagulopathy review before the procedure date
- Add CDT isoelectric focusing and mass spectrometry platforms with immediate laboratory-hours alerting — the Type I CDG pattern is the biochemical gateway for ALG1-CDG diagnosis, and 6-monthly repeat CDT monitoring contributes the longitudinal glycosylation biomarker dataset for natural history documentation
- Configure ALG1 molecular genetics platforms with immediate laboratory-hours alerting for biallelic variant identification, family cascade evaluation, and prenatal testing in at-risk families
- Add hepatic function monitoring platforms with immediate laboratory-hours alerting for CDG hepatopathy surveillance and hepatotoxic anti-epileptic drug safety
- Configure brain MRI scheduling with immediate clinical-hours alerting for annual white matter and cortical atrophy progression documentation and sedation procedure planning
- Add vigabatrin visual field monitoring scheduling with sustained-failure alerting — ophthalmologic visual field testing at initiation, 3, 6, and 12 months if vigabatrin is used for infantile spasm management, plus ERG monitoring for retinotoxicity in non-verbal patients
- Configure physiotherapy scheduling platforms with sustained-failure alerting for weekly or biweekly gross motor and hypotonia rehabilitation scheduling
- Add occupational therapy platforms with sustained-failure alerting for fine motor, feeding, and AAC program scheduling
- Configure speech-language pathology scheduling with sustained-failure alerting for oromotor and communication program management
- Add assistive technology assessment scheduling with sustained-failure alerting for biannual AAC, mobility, and daily living device review
- Configure gastrostomy and nutritional support records platforms with sustained-failure alerting for tube feeding management, caloric intake monitoring, and vitamin K supplementation
- Add school support and IEP planning systems with sustained-failure alerting for biannual educational planning in children with global developmental delay
- Configure family cascade molecular testing platforms with sustained-failure alerting for at-risk sibling presymptomatic diagnosis enabling early monitoring before infantile spasm onset
- Enable SSL certificate monitoring across all EEG, coagulation, CDT analysis, ALG1 genetics, hepatic function, brain MRI, rehabilitation scheduling, and IWGCDG/CDG Care registry platforms — and add the status page URL to ALG1-CDG clinic infantile spasm escalation protocols, EEG downtime procedures, and pre-procedural coagulopathy backup plans
Conclusion
ALG1-CDG technology platforms are embedded in clinical decisions where EEG platform availability for a 4-month-old with ALG1-CDG presenting with a 10-day history of clusters of sudden flexion spasms occurring on waking from sleep — when the EEG platform required to demonstrate the chaotic, high-amplitude, multifocal discharge pattern on a disorganized background constituting hypsarrhythmia, confirming the diagnosis of West syndrome, and directing the immediate initiation of ACTH treatment at 150 IU/m2 is unavailable during the urgent neurological assessment — delays the infantile spasm diagnosis and ACTH initiation by 3 days, during which hypsarrhythmia continues to disrupt normal cortical network function and inflicts additional epileptic encephalopathy injury on the frontal and temporal association areas that subserve the language, executive function, and social cognition that are the developmental goals of the multi-specialty rehabilitation program this child will need across childhood; where EEG platform availability at day 14 of ACTH treatment for the same patient — when the day-14 EEG required to confirm that hypsarrhythmia has resolved (demonstrating successful ACTH response) or has persisted (mandating urgent escalation to vigabatrin or nitrazepam as a second-line agent) is unavailable and the follow-up EEG is deferred to day 21 — allows 7 additional days of possible persistent hypsarrhythmia before the treatment failure is recognized and escalation initiated, with each day of active hypsarrhythmia representing continued epileptic encephalopathy injury; and where pre-procedural coagulation assessment platform availability for the same patient at age 18 months when a lumbar puncture is required for CSF evaluation during a febrile status epilepticus event — when the coagulation platform delivering the factor XI at 32%, protein C at 24%, and protein S at 27% that requires the neurologist to request hematology consultation before LP to plan whether the procedure can proceed at standard technique or requires modification for the compound coagulopathy is unavailable, and the LP is performed before coagulation results return — exposes the patient to a spinal hematoma risk in the context of protein C and protein S deficiency without the pre-procedural hematology assessment that would have guided the risk-benefit discussion.
Uptime monitoring gives ALG1-CDG tech teams the detection capability to identify failures within seconds, trigger immediate clinical downtime procedures, and demonstrate to metabolic medicine centers, pediatric neurology programs and infantile spasm management units, neurophysiology departments, hematology services, hepatology departments, molecular genetics laboratories, dietetics services, physiotherapy and occupational therapy programs, speech-language pathology departments, and IWGCDG / CDG Care registry coordination programs that platform operational reliability matches the infantile spasm urgency, coagulopathy management complexity, neurodevelopmental surveillance obligations, hepatic monitoring demands, and multi-specialty rehabilitation coordination complexity of modern ALG1-CDG care.
Start monitoring your ALG1-CDG care tech platform for free at vigilmon.online — HTTP/HTTPS monitoring, multi-region consensus alerting, SSL certificate monitoring, automatic status page, Slack and webhook alerts. No agent required. No credit card.
Tags: #monitoring #ALG1CDG #CDG #CongenitalDisorderOfGlycosylation #CDGIk #ALG1 #mannosyltransferase #infantileSpasms #WestSyndrome #hypsarrhythmia #ACTH #vigabatrin #epilepticEncephalopathy #coagulopathy #glycosylation #transferrinCDG #rareDisease #metabolicDisease #HIPAA #healthtech #digitalhealth #uptime #sre